We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+33.77%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.6B
AUM Growth
+$3.41B
Cap. Flow
-$91.9M
Cap. Flow %
-0.59%
Top 10 Hldgs %
85.51%
Holding
100
New
7
Increased
16
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$48.4M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.8M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$23.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$11.1M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$115M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.5M
3
ARRY
Array Biopharma Inc
ARRY
+$25M
4
SLDB icon
Solid Biosciences
SLDB
+$15.8M
5
NVAX icon
Novavax
NVAX
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 99.44%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$3.74B 23.93%
51,049,760
+3,700
+0% +$263K
INCY icon
2
Incyte
INCY
$25.9B
$2.95B 18.87%
34,271,827
+20,220
+0.1% +$1.65M
ONC
3
BeOne Medicines Ltd
ONC
$42.4B
$1.58B 10.11%
11,959,824
– –
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$1.16B 7.41%
8,558,068
+2,174
+0% +$270K
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$1.07B 6.83%
39,713,842
– –
AMRN
6
Amarin Corp
AMRN
$298M
$897M 5.74%
2,160,523
+30,882
+1% +$11.1M
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$714M 4.57%
10,198,943
-1,545,067
-13% -$115M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.9B
$674M 4.32%
7,589,294
– –
ASND icon
9
Ascendis Pharma A/S
ASND
$16.6B
$399M 2.55%
3,390,270
+552,918
+19% +$48.4M
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$184M 1.18%
2,513,462
– –
MDGL icon
11
Madrigal Pharmaceuticals
MDGL
$11.9B
$146M 0.94%
1,169,278
– –
ARGX icon
12
argenx
ARGX
$65B
$127M 0.81%
1,019,557
– –
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.44B
$123M 0.79%
15,118,081
+15,000
+0.1% +$128K
HRTX icon
14
Heron Therapeutics
HRTX
$60.4M
$123M 0.79%
5,018,104
– –
CMTA
15
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$97.2M 0.62%
3,724,445
– –
NBIX icon
16
Neurocrine Biosciences
NBIX
$15.5B
$96.8M 0.62%
1,098,670
+368,315
+50% +$30.8M
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$93.7M 0.6%
3,842,289
-1,199,407
-24% -$25M
NVTA
18
DELISTED
Invitae Corporation
NVTA
$91.4M 0.59%
3,902,421
– –
ONCE
19
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$85.6M 0.55%
751,927
-632,203
-46% -$46.5M
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
$75.8M 0.49%
5,707,411
+789,711
+16% +$8.4M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$7.57B
$74.2M 0.48%
2,708,200
– –
GWPH
22
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$72.2M 0.46%
428,345
– –
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
$69.6M 0.45%
1,803,238
+203,238
+13% +$4.73M
CERS icon
24
Cerus
CERS
$566M
$67M 0.43%
10,749,937
– –
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
$66.9M 0.43%
1,715,183
+804,720
+88% +$23.1M
1
2 3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2019 Portfolio in Review

As of Q1 2019, Julian Baker held 100 positions worth $15.6B, up 28% from $12.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q1 2019 filing shows 7 new, 16 increased, 6 reduced and 4 closed positions. Its largest new stake was Axsome Therapeutics: 1,200,000 shares worth $17.1M. The largest sale was Genomic Health, Inc., an estimated $115M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q1 2019 buy was Axsome Therapeutics: 1,200,000 shares worth $17.1M.
  • Julian Baker added most to Ascendis Pharma A/S in Q1 2019, an estimated $48.4M increase.
  • Julian Baker's biggest Q1 2019 reduction was Genomic Health, Inc., cutting an estimated $115M.
  • Julian Baker fully exited Solid Biosciences in Q1 2019, selling an estimated $15.8M.
  • Julian Baker's ten largest holdings make up 86% of its $15.6B portfolio in Q1 2019.
  • Julian Baker opened 7 new positions and closed 4 in Q1 2019.
  • Julian Baker's portfolio value rose 28% quarter-over-quarter to $15.6B.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.